LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
PRME
Prime Medicine, Inc.
There isn't enough reported data to score PRME yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PRME Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
PRME's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
PRME PE Valuation
PRME has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
PRME Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Moderate | |
| Low |
Analysts expect PRME's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over PRME on earnings quality, reporting a profit while its opponent remains loss making.
PRME Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.96 | +$0.48 |
| Q2 2026 | -$1.06 | +$0.50 |
| Q1 2026 | -$1.23 | +$0.38 |
| Q4 2025 | -$1.35 | +$0.30 |
| Q3 2025 | -$1.44 | +$0.62 |
| Q2 2025 | -$1.56 | +$0.61 |
| Q1 2025 | -$1.61 | +$0.57 |
| Q4 2024 | -$1.65 | +$0.53 |
PRME is still losing money, but far less than before: $0.96 per share over the past year, against $3.02 at its worst in late 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
PRME has the stronger quarterly revenue trend. Revenue is up 39% for LLY versus up 190% for PRME.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over PRME on profitability, with a higher operating margin.
PRME Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.2M | +244% |
| Q4 2025 | $838K | -62% |
| Q3 2025 | $1.2M | +486% |
| Q1 2025 | $1.5M | +146% |
PRME's revenue is growing: $4M last quarter, up 190% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -948% | +3458 points |
| Q4 2025 | -5800% | -3775 points |
| Q3 2025 | -4406% | +21542 points |
| Q2 2025 | -4787% | N/A |
| Q1 2025 | -3603% | +4576 points |
| Q4 2024 | -2026% | N/A |
| Q3 2024 | -25948% | N/A |
| Q1 2024 | -8180% | N/A |
PRME's operating margin was −948% last quarter, up 2656 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over PRME on cash generation, producing positive trailing cash flow while its opponent burns cash.
PRME Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$37M | -$1.7M |
| Q2 2026 | -$41.1M | +$1.9M |
| Q1 2026 | -$42.9M | +$8.4M |
| Q4 2025 | -$37.5M | -360% |
| Q3 2025 | -$35.3M | -$8.1M |
| Q2 2025 | -$43M | +$4.4M |
| Q1 2025 | -$51.3M | +$18.8M |
| Q4 2024 | $14.5M | +$60.2M |
PRME has burned cash in almost every quarter: −$159M over the past year, against −$115M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over PRME on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PRME Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +632K shares |
| 1 year | +11% | +17.4M shares |
| 3 years | +97% | +87.4M shares |
| 5 years | +86% | +82.1M shares |
PRME has 178M diluted shares, up 11% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q4 2019 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
PRME Net Leverage
PRME's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PRME Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.1 | Neutral |
| Stochastic | 53.0 | Neutral |
PRME's weekly RSI is 53 (neutral) and its Stochastic is 53 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
PRME PE vs Healthcare Sector
PRME has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over PRME on trend strength, trading above more of its moving averages.
PRME Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.78 | 2.9% above |
| 20 week MA | $3.50 | 11% above |
| 50 week MA | $3.54 | 9.9% above |
| 100 week MA | $3.31 | 18% above |
| 200 week MA | $6.15 | 37% below |
PRME has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 37% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over PRME on returns for 2026, with the stronger performance.
PRME Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $15.8 | $17.8 | +13% |
| 2023 | $17.8 | $8.86 | -50% |
| 2024 | $8.86 | $2.90 | -67% |
| 2025 | $2.90 | $3.50 | +21% |
| 2026 YTD | $3.50 | $3.89 | +11% |
PRME has finished lower in two of the last four years. It's up 11% so far in 2026.